ERBB2 and gastric cancer: In the last few decades, HER2-directed therapies, such as trastuzumab, a humanized monoclonal antibody targeting the HER2 receptor, have dramatically transformed outcomes for patients with HER2-positive breast and stomach cancers.8 By comparison, HER2-targeted therapies in CRC have been less of a focus until recent years.